Intas Pharmaceuticals Alternatives & Competitors
5 companies similar to Intas Pharmaceuticals — Expressions for a Healthy Life
Companies similar to Intas Pharmaceuticals
AbbVie
Pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and s...
Boehringer Ingelheim
Boehringer Ingelheim - researching, developing, manufacturing and marketing of pharmaceuti...
Track all Intas Pharmaceuticals competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Akums Drugs& Pharmaceuticals Ltd
Ensuring Healthier, Happier Lives
About Intas Pharmaceuticals
Intas Pharmaceuticals, founded in 2000, stands as a leading multinational organization in the pharmaceutical formulation sector, with a progressive 19% CAGR and impressive revenues surpassing the $2.5 billion mark. The company's extensive global reach spans over 85+ countries, with 70% of revenue generated internationa...
Pharmaceutical Formulation Development, Manufacturing, R&D, Biologics, Plasma Fractionation
Healthcare Professionals, International Markets in EU and US, Patients with Chronic Conditions
Pharmaceutical Formulation Development, Generic Pharmaceuticals, Biosimilars, Central Nervous System, Oncology, Plasma-Derived Therapeutics, Biopharma Division, Novel Drug Delivery Systems (NDDS), Research And Development, Recombinant Proteins Manufacturing, Therapeutic Segments, Chronic Therapies, Regulated Markets, Product Registrations, Innovative APIs
B2B
Product Sales, Licensing
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Intas Pharmaceuticals and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Intas Pharmaceuticals on 25 Mar 2026. The 5 companies listed here were last checked between 12 Sep 2024 and 23 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.